Systemic Left Sided Hypertensive Heart Disease

Slide 1 · Systemic (Left-Sided)

Hypertensive Heart Disease

Pressure overload · myocardial remodeling · clinicopathologic consequences

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Explain why persistent systemic hypertension produces predominantly concentric LV hypertrophy.

Recognize gross and microscopic criteria and their diagnostic limitations.

Connect fibrosis and chamber stiffness with atrial enlargement, ischemia and heart failure.

Distinguish hypertensive remodeling from major mimics and apply pathology findings to cases.

Slide 3 · Hypertensive heart disease is pressure-overload injury

Systemic hypertension

LV pressure overload

Myocyte hypertrophy

Remodeling and dysfunction

Chronic systemic hypertension increases the mechanical work required of the left ventricle.

Cardiomyocytes enlarge, producing ventricular hypertrophy and increased myocardial mass.

Compensation can persist for years before maladaptive remodeling and clinical disease emerge.

Slide 4 · Systemic and pulmonary pressure loads affect different ventricles

Systemic hypertension

Left ventricular afterload

Concentric LV hypertrophy

May enlarge left atrium

Pulmonary hypertension

Right ventricular afterload

Right ventricular hypertrophy

Separate cor pulmonale syndrome

Clinical–pathologic interpretation

Systemic arterial hypertension predominantly loads the left ventricle.

Pulmonary vascular hypertension primarily loads the right ventricle (cor pulmonale).

The site of pressure elevation identifies which chamber is directly overloaded.

Slide 5 · Chronic pressure overload creates a compensatory–maladaptive continuum

Adaptive growth

Stiffer ventricle

Demand ischemia

Decompensation

Early hypertrophy helps sustain cardiac function against raised arterial resistance.

Continued stress adds myocardial fibrosis and impaired relaxation.

Later stages can include ischemia, chamber dilation, failure and sudden cardiac death.

Slide 6 · The ventricle must generate higher systolic pressure

Higher arterial pressure

Greater LV wall stress

Growth stimulus

Increased LV mass

An elevated systemic arterial pressure is an increased ejection load (afterload).

Greater pressure demands more myocardial wall tension during systole.

The structural response is growth of the ventricular myocardium rather than a rise in myocyte number.

Slide 7 · Concentric remodeling reduces pressure-related wall stress

With pressure loading, the myocardial wall thickens relative to the cavity.

Normal LV

Hypertensive LV

Higher myocardial mass with a smaller relative cavity

Slide 8 · Exposure duration matters—not only a single pressure reading

Prolonged elevated BP

Repeated pressure loading

LV hypertrophy

Fibrotic remodeling

Prolonged even relatively mild hypertension as sufficient to cause LVH.

Chronicity allows cumulative cardiomyocyte growth and matrix deposition.

Absence of dramatic blood pressure at a single examination does not exclude prior sustained hypertension.

Slide 9 · Blood-pressure cutoffs differ between clinical frameworks

American framework (as described)

Around 130/80 mm Hg

Broader clinical classification

European framework (as described)

Around 140/90 mm Hg

Different case definition

Clinical–pathologic interpretation

An American heart association threshold around 130/80 mm Hg.

The same text contrasts a European hypertension definition around 140/90 mm Hg.

These historical textbook comparisons are not morphologic criteria for HHD or a current treatment algorithm.

Slide 10 · Pathologic diagnosis requires a two-part argument

LV hypertrophy

Exclude another sufficient cause

Evidence of hypertension

Systemic HHD

Left ventricular hypertrophy—usually concentric—without another sufficient cardiovascular cause.

Independent clinical history or pathologic evidence of systemic hypertension.

Neither myocardial wall thickening nor hypertension alone establishes the complete morphologic diagnosis.

Slide 11 · Criterion 1: A hypertrophied left ventricle

Concentric LVH is the characteristic geometric response to persistent pressure overload.

Concentric LVH

Thick ventricular myocardium; Initially nondilated chamber

Slide 12 · Criterion 2: Hypertension supported beyond the heart

Clinical BP history

Or renal/vascular evidence

Correlate with LV findings

Attribution to hypertension

Clinical documentation of a sustained hypertensive history is directly relevant.

Robbins explicitly allows pathologic evidence of hypertension in other organs, such as the kidneys.

Cardiac findings must be interpreted alongside extracardiac vascular and renal changes.

Slide 13 · Excluding other causes prevents circular diagnosis

Compatible with HHD

Concentric LVH

Sustained systemic hypertension

No better alternative

Requires alternative evaluation

Severe valve obstruction

Unexplained hypertrophy

Infiltrative features

Clinical–pathologic interpretation

Aortic stenosis can produce marked pressure-overload LVH without primary systemic hypertension.

Hypertrophic cardiomyopathy can produce a heavy, thick-walled ventricle.

Infiltrative and other myocardial diseases may impair filling and mimic part of the phenotype.

Slide 14 · A practical pathology attribution sequence

Confirm LVH

Review alternative causes

Find hypertension evidence

Integrate pathology + history

Identify the dominant ventricular abnormality: Thickening, chamber dilation, or both.

Assess valve disease, outflow tract anatomy and other relevant cardiac lesions.

Integrate systemic blood-pressure history and extracardiac hypertensive changes.

Slide 15 · Pressure overload and volume overload remodel differently

Pressure overload

Parallel sarcomere assembly

Myocyte cross-section ↑

Concentric LV thickening

Volume overload

Sarcomeres assembled in series

Myocyte length ↑

Chamber dilation dominates

Clinical–pathologic interpretation

Pressure overload typically adds sarcomeres in parallel and increases wall thickness.

Volume overload predominantly adds sarcomeres in series and increases chamber dimensions.

Dilated failing hearts may be hypertrophied even if wall thickness is not striking.

Slide 16 · Parallel sarcomere addition enlarges myocyte cross-section

Existing cardiomyocytes increase their contractile apparatus rather than multiplying.

Normal-caliber cardiomyocytes

Transverse hypertrophy

Conceptual tissue schematic—not a histology image

Slide 17 · Hypertrophy requires a biosynthetic response

Mechanical loading

Protein synthesis ↑

Sarcomeres + mitochondria ↑

Larger myocyte

Increased protein synthesis builds the contractile machinery needed for larger cells.

Mitochondrial content rises to meet the energetic requirements of expanded myocardium.

Greater myocardial mass creates metabolic obligations that persist throughout the cardiac cycle.

Slide 18 · Enlarged nuclei accompany advanced myocyte growth

Cardiac hypertrophy is often associated with enlarged or multiple cardiomyocyte nuclei.

Ordinary cardiomyocyte nucleus

Hypertrophied cardiomyocyte + nucleus

Conceptual tissue schematic—not a histology image

Slide 19 · Capillary density does not rise proportionally with myocyte mass

Normal relation

Myocyte mass and microvasculature appropriately matched

Lower relative oxygen demand

Hypertrophied myocardium

More muscle per available capillary

Less supply reserve

Clinical–pathologic interpretation

Hypertrophied myocardium is not matched by an equivalent increase in microvascular density.

Oxygen and nutrient delivery become relatively less robust for the expanded muscle mass.

This mismatch contributes to vulnerability during hemodynamic stress.

Slide 20 · A larger left ventricle consumes more oxygen

LV mass ↑

Oxygen demand ↑

Supply reserve limited

Myocardial ischemia

Increased myocardial mass elevates aggregate metabolic demand.

Higher heart rate and stronger contractility can further raise oxygen consumption.

In a supply-limited ventricle, physiological exertion can unmask ischemia.

Slide 21 · “Demand” ischemia need not require acute coronary occlusion

Myocardial demand mechanism

Increased muscle mass

Greater myocardial oxygen needs

Limited capillary reserve

Coronary vascular mechanism

Atherosclerotic disease risk ↑

Potential coronary flow limitation

Can coexist with LVH

Clinical–pathologic interpretation

Hypertrophy can increase oxygen needs beyond available perfusion reserve.

Robbins separately highlights hypertension-mediated potentiation of coronary atherosclerosis.

Both supply–demand mismatch and epicardial coronary disease can contribute to ischemic injury.

Slide 22 · Pressure loading also activates extracellular-matrix remodeling

Sustained LV wall stress

Fibroblast response

Interstitial collagen ↑

Myocardial stiffness ↑

Mechanical stimuli influence cardiac fibroblasts as well as cardiomyocytes.

Increased extracellular-matrix synthesis accompanies chronic overload.

Interstitial collagen increases resistance to diastolic filling.

Slide 23 · Perivascular fibrosis is part of the microscopic pattern

Fibrosis around myocardial vessels in more advanced HHD.

Sparse interstitial connective tissue

Expanded interstitium (fibrosis)

Conceptual tissue schematic—not a histology image

Slide 24 · Fibrosis and hypertrophy act together to impair relaxation

Myocyte enlargement

Interstitial fibrosis

Reduced LV compliance

Higher filling pressure

Enlarged cardiomyocytes alter chamber structure and myocardial material properties.

Excess interstitial connective tissue increases wall stiffness.

The ventricle needs higher filling pressures to accommodate blood during diastole.

Slide 25 · A stiff LV develops impaired diastolic filling

Thick + fibrotic LV

Stiff chamber

Poor diastolic filling

Elevated LV filling pressure

Concentric LVH initially may preserve chamber contraction despite abnormal relaxation.

Reduced compliance limits ventricular expansion in diastole.

Filling pressure can rise even when ejection fraction remains relatively preserved.

Slide 26 · Left atrial enlargement is a downstream pressure signal

LV diastolic stiffness

Raised filling pressure

Left atrial enlargement

Atrial fibrillation risk

Impaired LV filling increases upstream pressure burden on the left atrium.

Chronic pressure loading may enlarge the atrial chamber.

Left atrial enlargement with a later risk of atrial fibrillation.

Slide 27 · Atrial fibrillation can be the first obvious clinical event

Silent LVH

Left atrial enlargement

Atrial fibrillation

Clinical detection

A patient may have unrecognized compensated LVH for years.

Left atrial enlargement predisposes to atrial fibrillation in the clinical course.

New atrial fibrillation warrants assessment for underlying hypertensive structural disease.

Slide 28 · Compensated HHD may have no symptoms

Anatomic state

Increased LV mass

Concentric geometry

May be LA enlarged

Clinical state

Asymptomatic compensation

ECG or echocardiographic detection

No overt CHF yet

Clinical–pathologic interpretation

Structural LV enlargement can precede overt functional limitation.

Patients may have only electrocardiographic or echocardiographic evidence of abnormality.

A quiet clinical history therefore does not exclude an established hypertensive myocardial response.

Slide 29 · Compensation can ultimately be exhausted

Concentric LVH

Fibrotic stiffening

LV dilation

Clinical heart failure

Persistent pressure loading and fibrotic remodeling can impair myocardial performance.

An initially thick and nondilated chamber may later dilate.

Advanced decompensation can include overt congestive heart failure.

Slide 30 · Dilation changes how hypertrophy appears grossly

An advanced failing ventricle may have both increased mass and a larger cavity.

Normal

Concentric LVH

Hypertrophied + dilated

Diagrammatic geometry—not a scale drawing

Slide 31 · Systolic and diastolic failure represent distinct dysfunctions

Diastolic-dominant failure

Stiff LV chamber

Impaired filling

Ejection fraction may be preserved

Systolic-dominant failure

Impaired LV contraction

Reduced ejection fraction

Often accompanies dilation

Clinical–pathologic interpretation

Systolic dysfunction: Impaired contractile emptying and reduced ejection fraction.

Diastolic dysfunction: Inadequate filling due to reduced compliance or relaxation.

Hypertensive remodeling often begins with diastolic abnormalities; Late disease may combine both.

Slide 32 · Heart-failure phenotype is not defined by wall thickness alone

Preserved EF phenotype

Often diastolic predominant

LV stiff/poor filling

Hypertension is a common basis

Reduced EF phenotype

Systolic pumping deficit

May accompany ventricular dilation

Clinical heart-failure syndrome

Clinical–pathologic interpretation

Heart failure with preserved versus reduced ejection fraction.

Anatomic LVH can coexist with impaired filling despite preserved EF.

Clinical function, imaging and examination remain necessary alongside gross pathology.

Slide 33 · Diastolic pressure may transmit backward to the lungs

LV filling pressure ↑

Left atrial pressure ↑

Pulmonary venous congestion

Dyspnea / edema

High LV filling pressure can propagate to the left atrium and pulmonary veins.

Pulmonary venous congestion impairs gas exchange and contributes to dyspnea.

Fluid can move into pulmonary interstitium/alveoli as decompensation worsens.

Slide 34 · Low forward output produces systemic consequences

Reduced forward output

Renal perfusion ↓

Salt/water retention

Congestion worsens

Advanced failure can reduce blood flow available for tissue metabolic requirements.

Renal hypoperfusion may trigger neurohumoral compensation and sodium retention.

Fluid retention can worsen congestion even when initially intended to support perfusion.

Slide 35 · Concentric LV thickening is the gross hallmark

Left ventricular wall thickness increases disproportionately to cavity size.

Normal LV

Hypertensive LV

Higher myocardial mass with a smaller relative cavity

Slide 36 · The ventricular lumen can become relatively small

For a similarly sized outer silhouette, more tissue around the lumen leaves less cavity space.

Normal LV

Hypertensive LV

More ventricular muscle encroaches on the cavity

Slide 37 · Cardiac mass may increase more than the external dimensions

Overall appearance

External dimensions may rise modestly

LV cavity initially nondilated

Actual myocardial burden

LV wall mass substantially ↑

Cardiac weight disproportionately ↑

Clinical–pathologic interpretation

Concentric hypertrophy adds myocardium without a proportional increase in overall heart size.

A specimen can therefore be markedly heavy despite limited apparent cardiomegaly.

Weight and chamber geometry should both be documented at gross examination.

Slide 38 · Potentially marked enlargement

In severe systemic HHD, heart weight may exceed 500 g.

Left ventricular wall thickness may exceed 2.0 cm.

These are illustrative severe morphologic findings—not obligatory diagnostic cutoffs.

Marked thickening is possible; The complete diagnosis still requires hypertensive attribution.

Slide 39 · A gross examination should integrate multiple observations

Cardiac weight

LV geometry

Valve / outflow / coronaries

Clinicopathologic synthesis

Assess overall heart weight and ventricular chamber geometry.

Inspect LV wall thickening and ventricular cavity size together.

Examine valves, outflow anatomy and coronary arteries for competing or coexisting lesions.

Slide 40 · Earliest microscopic change: Myocyte diameter increases

Transverse enlargement may be subtle on routine histologic sections.

Normal-caliber cardiomyocytes

Transverse hypertrophy

Conceptual tissue schematic—not a histology image

Slide 41 · Advanced disease shows conspicuous cellular and nuclear growth

Myocytes can become visibly broad with enlarged nuclei.

Ordinary cardiomyocyte nucleus

Hypertrophied cardiomyocyte + nucleus

Conceptual tissue schematic—not a histology image

Slide 42 · Interstitial collagen accumulates between muscle fibers

Interstitial fibrosis separates and surrounds cardiac myocytes.

Sparse interstitial connective tissue

Expanded interstitium (fibrosis)

Conceptual tissue schematic—not a histology image

Slide 43 · Hypertrophy and fibrosis explain different functional burdens

Myocyte hypertrophy

Higher myocardial mass

Pressure-load adaptation

Greater oxygen demand

Interstitial fibrosis

Less compliant LV

Abnormal relaxation

Higher filling pressures

Clinical–pathologic interpretation

Hypertrophy improves force-generating capacity but raises oxygen requirements.

Fibrosis limits compliance and interferes with efficient filling.

Together, they help explain why a thick ventricle may be both ischemia-prone and dysfunctional.

Slide 44 · ECG and echocardiography detect silent LV remodeling

Electrocardiography

Electrical indices of LVH

Rhythm assessment

Evidence is indirect

Echocardiography

Wall geometry and chamber dimensions

LV systolic / diastolic physiology

Structural visualization

Clinical–pathologic interpretation

Electrocardiographic or echocardiographic evidence of LV enlargement in compensated disease.

ECG provides indirect evidence of hypertrophy and rhythm abnormalities.

Echocardiography directly assesses wall thickness, chamber dimensions and function.

Slide 45 · Histology alone does not establish the cause of LVH

Myocyte enlargement

Fibrosis

Gross cardiac pattern

Clinical + etiologic correlation

Enlarged myocytes and fibrosis are shared responses to cardiac stress.

Microscopic findings must be matched to chamber distribution and gross geometry.

Hypertension history and exclusion of other cardiac lesions determine attribution.

Slide 46 · Clinical presentation often reflects filling abnormalities

Reduced LV compliance

Elevated filling pressure

Pulmonary congestion

Exertional symptoms

A stiff LV may have reduced filling reserve during increased demand.

Progressive congestion can cause exertional breathlessness and ultimately CHF.

Symptoms depend on the stage of remodeling, coexisting coronary disease and treatment history.

Slide 47 · Hypertension and coronary atherosclerosis can reinforce risk

Hypertension

Coronary disease propensity + LVH

Supply–demand imbalance

Ischemic heart disease

Hypertension accelerates coronary atherosclerotic risk’ discussion.

Greater LV mass simultaneously increases myocardial oxygen demand.

The combination makes ischemic heart disease an important HHD complication.

Slide 48 · Systemic hypertension may injure multiple organs

Cardiac consequences

LVH and ischemia

Atrial fibrillation

Congestive heart failure

Extracardiac consequences

Renal hypertensive injury

Cerebrovascular stroke

Systemic vascular damage

Clinical–pathologic interpretation

Renal damage and cerebrovascular stroke among clinical outcomes.

Not all adverse outcomes of systemic hypertension depend on heart failure.

Extracardiac vascular injury also strengthens evidence for a systemic hypertensive disorder.

Slide 49 · Sudden cardiac death is a possible late outcome

Hypertrophy + fibrosis

Ischemic vulnerability

Electrical instability

Possible SCD

Sudden death among the possible complications of HHD.

Advanced hypertrophy, fibrosis and ischemic injury may create an arrhythmogenic substrate.

Its occurrence is not inevitable and must not be inferred from wall thickness alone.

Slide 50 · Clinical courses are heterogeneous

Compensated trajectory

Stable structure/function

Possible normal longevity

Unrelated cause of death

Complicated trajectory

IHD or atrial fibrillation

CHF / sudden death

Renal injury or stroke

Clinical–pathologic interpretation

Well-controlled individuals may remain compensated and have a normal life span.

Others may develop ischemic heart disease, atrial fibrillation or progressive heart failure.

Renal disease, stroke and sudden death are additional outcomes described by the textbook.

Slide 51 · Outcome depends on exposure and control

Pressure severity

Duration of exposure

Therapeutic control

Patient trajectory

Severity and duration of hypertension affect the myocardial response.

Underlying basis of the pressure elevation and effectiveness of treatment also matter.

There is no single inevitable transition from concentric LVH to overt failure.

Slide 52 · Blood-pressure control can prevent or reverse hypertrophy

Lower afterload

Less growth stimulus

LVH regression possible

Reduced HHD risk

Effective treatment can prevent cardiac hypertrophy.

Established LVH may regress when the pressure stimulus is reduced.

Normalization of blood pressure can lower associated HHD risks.

Slide 53 · Structural regression has mechanistic significance

Control systemic BP

Reduce LV mechanical stress

Remodeling may regress

Follow structure + function

Less chronic pressure load reduces the drive for pathologic myocyte growth.

Functional and structural recovery may not proceed identically in every individual.

Disease monitoring should integrate blood pressure, ventricular geometry and clinical status.

Slide 54 · Aortic stenosis is a major pressure-overload mimic

Systemic HHD

Systemic arterial afterload elevated

Hypertension evidence required

Exclude other sufficient causes

Aortic stenosis

Valvular LV outflow obstruction

Pressure overload despite other BP patterns

Valve pathology is causal

Clinical–pathologic interpretation

Aortic valve obstruction can itself produce concentric LVH.

Gross myocardial thickening cannot distinguish the arterial from valvular pressure source.

Valve inspection and clinical imaging are therefore essential before diagnosing primary systemic HHD.

Slide 55 · Hypertrophic cardiomyopathy requires distinct evaluation

Typical hypertensive pattern

Systemic hypertension

Usually concentric LVH

Fibrosis / myocyte enlargement

Typical HCM pattern

Often familial / sarcomeric

Often asymmetric septal LVH

Myocyte disarray + fibrosis

Clinical–pathologic interpretation

Hypertrophic cardiomyopathy is often inherited and associated with sarcomeric variants.

Classic morphology frequently shows disproportionate septal hypertrophy and myofiber disarray.

HCM may sometimes be concentric; No single gross feature reliably replaces clinicopathologic correlation.

Slide 56 · Restrictive and infiltrative processes may mimic diastolic HHD

Hypertensive stiffening

Pressure-load history

Cardiomyocyte hypertrophy

Interstitial fibrosis

Infiltrative/restrictive process

Abnormal myocardial deposits or fibrosis

Restrictive filling

Different etiologic workup

Clinical–pathologic interpretation

Cardiac amyloidosis and other infiltration disorders can impair LV compliance.

Impaired filling and atrial dilation are not unique to hypertensive myocardial disease.

An unexpected clinical–morphologic pattern merits investigation for nonhypertensive causes.

Slide 57 · Chamber dilation does not exclude previous hypertrophy

Dilated myocardium can remain hypertrophied even with a near-normal-looking wall.

Normal

Concentric LVH

Hypertrophied + dilated

Diagrammatic geometry—not a scale drawing

Slide 58 · Etiologic comparison of major LVH phenotypes

Process

Dominant stimulus

Helpful discriminator

Systemic HHD

Systemic pressure load

Documented hypertension

Aortic stenosis

Valvular pressure load

Obstructive valve lesion

HCM

Primary sarcomeric disease

Family history / disarray

Volume overload

Chamber volume load

Dilation / regurgitation

Systemic hypertension: Usually concentric LVH with an appropriate systemic pressure history.

Aortic stenosis: Concentric LVH from fixed left ventricular outflow obstruction.

Slide 59 · Teaching case: Incidental concentric hypertrophy

Hypothetical scenario: An asymptomatic person with prolonged hypertension has echo-detected LVH.

The absence of dyspnea does not negate morphologic remodeling.

Ask: Which additional findings would strengthen the diagnosis of systemic HHD?

DISCUSSION: EXPECTED REASONING

Concentric LV geometry and hypertension history.

Assess valve disease and other LVH explanations.

Seek extracardiac hypertensive evidence if needed.

Slide 60 · Teaching case: New atrial fibrillation

Hypothetical scenario: Chronic hypertension, thick LV walls and a newly enlarged left atrium.

New atrial fibrillation prompts evaluation for impaired diastolic filling.

Ask: Trace the sequence from chronic pressure overload to the arrhythmia.

DISCUSSION: EXPECTED REASONING

Pressure overload → LVH and interstitial fibrosis.

Ventricular stiffness → higher filling pressure.

Left atrial enlargement → atrial fibrillation risk.

Slide 61 · Teaching case: Unexplained severe LVH

Hypothetical scenario: Marked LV thickening without a convincing hypertensive history.

The first morphologic diagnostic criterion may be present, but attribution remains incomplete.

Ask: What alternatives must be assessed before applying the systemic HHD label?

DISCUSSION: EXPECTED REASONING

Aortic stenosis or subvalvular obstruction.

Hypertrophic cardiomyopathy.

Infiltrative/restrictive myocardial disorders.

Slide 62 · A stepwise synthesis for pathologic diagnosis

Gross LVH

Supportive histology

Hypertension evidence

Exclude other etiologies

Systemic HHD

Confirm increased LV myocardial mass and characterize chamber geometry.

Identify myocyte hypertrophy and fibrosis as supportive microscopic findings.

Correlate hypertension history or systemic organ evidence and exclude major alternatives.

Slide 63 · Five causal relationships to retain

Hypertension → LV pressure overload → concentric hypertrophy.

Hypertrophy + fibrosis → stiff LV → impaired diastolic filling.

Elevated LV filling pressure → left atrial enlargement → atrial fibrillation.

Increased myocardial demand + limited perfusion reserve → ischemic vulnerability.

Persistent injury may culminate in dilation, failure or sudden death.

Compensation is useful initially; Structural adaptation can become a cause of dysfunction.

Slide 64 · Selected references and source scope

Robbins, Cotran & Kumar: Pathologic Basis of Disease, 11th edition (2026), Chapter 12: The Heart, pp 481–484 and 504–505.

Chapter 12, hypertrophic cardiomyopathy discussion, pp 520–521 (differential context).

Chapter 11, cardiovascular risk-factor discussion, p 451 (hypertension and coronary risk).

Conceptual cardiac cross-sections and histologic illustrations are original editable schematics, not clinical specimens.